



**\$159 Million**  
Secondary Offering

**svb** Securities  
Joint Bookrunner  
June 2023

## SVB Securities Serves as Joint Bookrunner for NewAmsterdam Pharma's (Nasdaq: NAMS) \$159 Million Secondary Offering

### Key Transaction Highlights

- Confidentially marketed deal that publicly launched June 6<sup>th</sup> (post-close) and priced overnight.
- Well oversubscribed from new and existing investors
- 100% secondary transaction that was upsized from 10.6mm ordinary shares to 13.9mm ordinary shares and priced at \$11.50 per share, representing a discount of 16.5% to last sale.
- This is SVB Securities' 1<sup>st</sup> bookrun offering for NewAmsterdam after having served as financial advisor and capital markets advisor on its de-SPAC merger in November 2022. This is also SVB Securities' 27<sup>th</sup> bookrun equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**

53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**

2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

**NASHVILLE**

40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**

1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**

255 California Street  
12th Floor  
San Francisco, CA 94111